Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gimatecan (ST1481) as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Randomized, Controlled Phase II Study

NCT04571489 is registered in ClinicalTrials.gov with Lee's Pharmaceutical Limited as lead sponsor.

NCT NCT04571489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04571489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gimatecan (ST1481) as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Randomized, Controlled Phase II Study
Lead sponsor
Lee's Pharmaceutical Limited
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2020
Completion date
December 1, 2023
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer